Amendments to the CLAIMS

1. (Currently amended) A compositon~~Composition~~, comprising a salt of O-acetylsalicylic acid with a basic amino acid,

   wherein said salt has an average particle size ~~above a particle size of~~ greater than 160 μm, and

   wherein said salt comprises salt particles, wherein ~~a proportion of~~ more than 60% of the particles have ~~having~~ a particle size ranging ~~in a range~~ from 100 to 200 μm in a particle size distribution measured using a Malvern 2600D apparatus under standard conditions, and

   wherein ~~characterized in that~~ the composition additionally comprises a flow improver or is granulated.

2. (Currently amended) The composition ~~Composition~~ according to claim 1, ~~characterized in that it comprises, as~~ wherein said flow improver comprises~~,~~ one or more saccharides.

3. (Currently amended) The composition ~~Composition~~ according to claim 1 [[2]], ~~characterized in that it~~ wherein said composition is dry-granulated.

4. (Currently amended) The composition ~~Composition~~ according to claim 1, ~~characterized in that the salt has an~~ wherein the average particle size is greater than ~~above a particle size of~~ 170 μm and wherein ~~a proportion of~~ more than 70% of the particles have ~~having~~ a particle size in a range from 100 to 200 μm in a particle size distribution measured using a Malvern 2600D apparatus under standard conditions.

5. (Currently amended) The composition ~~Composition~~ according to claim 1, ~~characterized in that~~ wherein the basic amino acid is selected from the group consisting of lysine, arginine, histidine, ornithine ~~or~~ and diaminobutyric acid.

6. (Currently amended) The composition ~~Composition~~ according to claim 1, wherein the composition ~~characterized in that it additionally comprises a proportion of from~~ further comprises glycine, at a concentration ranging from 5 to 15% by weight of glycine, based on the total amount of O-acetylsalicylate and glycine.

7. (Currently amended) A pharmaceutical ~~Pharmaceutical~~ composition, comprising ~~at least one~~ the composition according to claim 1.

8. (Currently amended) The pharmaceutical ~~Pharmaceutical~~ composition according to claim 7, ~~characterized in that it~~ wherein said pharmaceutical composition is provided as a single-dose, in solid ~~oral administration~~ form for oral administration.

9. (Currently amended) The pharmaceutical ~~Pharmaceutical~~ composition according to ~~as claimed in~~ claim 7, wherein said compostion ~~characterized in that it only~~ comprises only water-soluble ~~auxiliaries~~.

10. (Currently amended) The pharmaceutical ~~Pharmaceutical~~ composition according to claim 7, wherein said compostion ~~characterized in that it~~ is completely soluble in water.

11. (Currently amended) The pharmaceutical composition ~~Pharmaceutical~~ according to claim 7, wherein said compostion is ~~characterized in that it~~ further comprises one or more ~~further~~ additional pharmaceutically active compounds.

12. (Withdrawn-Currently amended) A method of treating a disorder selected from the group consisting of disorders of a rheumatic type, arthritis, neuralgia, myalgia ~~or~~ and migraine, comprising administering to a patient in need thereof an effective amount of ~~a~~ the composition of claim 1.

13. (Withdrawn, Currently amended) A method of treating ~~treating~~ a heart related disorder selected from the group consisting of ischaemic heart diseases, stroke, angina pectoris, myocardial infarction, bypass operations, PTCA ~~or~~ and stent implants, comprising administering to a patient in need thereof an effective amount of ~~a~~ the composition of claim 1.

14. (Withdrawn) A method for stimulating the immune system of HIV patients, for tumour prophylaxis, for slowing down the cognitive deterioration associated with dementia, for inhibiting the formation of gallstones or for treating diabetic disorders, comprising administering to a patient in need thereof an effective amount of a composition of claim 1.

15. (Currently amended) The pharmaceutical composition of claim 8, wherein the composition is a solid selected from the group consisting of a tablet, a chewable tablet, a soluble tablet, an enteric-coated tablet, a capsule and ~~or~~ a colon-targeted formulation.

16. (Currently amended) The pharmaceutical of claim 11, wherein the one or more additional pharmaceutically active compound is selected from the group consisting of ADP receptor antagonists, GPIIb/IIIa receptor antagonists, phosphodiesterase inhibitors, thrombin receptor antagonists, factor Xa inhibitors, HMG-CoA receptor antagonists and calcium antagonists.

17. (Previously presented) The composition of claim 2, wherein the flow improver is selected from the group consisting of mannitol, sorbitol, xylitol, and lactose, and a mixture thereof.

18. (Previously presented) The composition of claim 3, wherein the composition is roller-compacted.

19. (Previously presented) The pharmaceutical composition of claim 9, wherein the water-soluble auxiliary is a flow improver selected from the group consisting of mannitol, sorbitol, xylitol, and lactose, and a mixture thereof.